Alejandra Palacios, president of the Federal Commission of Economic Competition (COFECE) of Mexico, declared that a lack of competition and abuse of market power by certain pharmaceutical companies in collusion with public authorities has meant that “Mexican households pay an average of 98 percent more than they would pay without surcharges ” when buying medicines.
Featured News
States Seek 2027 Trial in Paramount-Warner Bros. Antitrust Case
Aug 2, 2026 by
CPI
New York Lawsuit Tests Prediction Market Regulation
Aug 2, 2026 by
CPI
SEC, Big Ten Back Senate College Sports Bill With Antitrust Protections
Aug 2, 2026 by
CPI
FTC Clears IonQ Acquisition of SkyWater Without Conditions
Aug 2, 2026 by
CPI
UK Watchdog Investigates Microsoft Over AI-Linked Subscription Pricing
Aug 2, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes